Research by Wistar Institute scientists shows how targeting a cleft in the retinoblastoma protein can kill tumor-protecting macrophages in ovarian cancer. The discovery provides a novel therapeutic target that could potentially make ovarian and other cancers more sensitive to immunotherapies.
Wistar Institute researchers have overturned three decades of scientific thinking about p53, the most important tumor suppressor protein in cancer research.
